WallStreetZenWallStreetZen

NASDAQ: GTBP
Gt Biopharma Inc Stock Ownership - Who owns Gt Biopharma?

Insider buying vs selling

Have Gt Biopharma Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Michael Martin BreenExecutive ChairmanInterim CEO2023-08-11200,000$0.29
$57.40kBuy
Manu OhriCFO Secretary2023-08-11200,000$0.29
$57.40kBuy
Manu OhriCFO Secretary2023-08-11200,000$0.29
$57.40kSell
Manu OhriCFO Secretary2023-08-11200,000$0.29
$57.40kBuy

1 of 1

GTBP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GTBP insiders and whales buy or sell their stock.

GTBP Shareholders

What type of owners hold Gt Biopharma Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Vanguard Group Inc78.80%1,087,993$3.97MInstitution
Michael Martin Breen62.02%856,218$3.13MInsider
Bank Of Montreal43.19%596,240$2.18MInstitution
Manu Ohri25.35%350,000$1.28MInsider
Geode Capital Management LLC24.43%337,315$1.23MInstitution
Blackrock Inc22.02%304,041$1.11MInstitution
Wells Fargo Company21.78%300,719$1.10MInstitution
Renaissance Technologies LLC8.31%114,695$418.64kInstitution
Atria Wealth Solutions Inc7.15%98,720$360.33kInstitution
Bank Of New York Mellon Corp6.90%95,239$347.62kInstitution

1 of 3

GTBP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GTBP73.85%26.15%Net Buying
PXMD1.39%98.61%Net SellingNet Selling
SNPX79.75%20.25%
PRTG11.46%0.00%
HOTH0.94%99.06%

Gt Biopharma Stock Ownership FAQ

Who owns Gt Biopharma?

Gt Biopharma (NASDAQ: GTBP) is owned by 246.72% institutional shareholders, 87.37% Gt Biopharma insiders, and 0.00% retail investors. Michael Martin Breen is the largest individual Gt Biopharma shareholder, owning 856,218.00 shares representing 62.02% of the company. Michael Martin Breen's Gt Biopharma shares are currently valued at $3.13M.

If you're new to stock investing, here's how to buy Gt Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.